Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 14,548 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 14,548 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $1.05, for a total transaction of $15,275.40. Following the completion of the transaction, the director directly owned 2,851,940 shares in the company, valued at approximately $2,994,537. The trade was a 0.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.08, for a total value of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total value of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total value of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total value of $31,951.62.

Werewolf Therapeutics Trading Down 43.8%

Shares of Werewolf Therapeutics stock traded down $0.47 during midday trading on Thursday, reaching $0.60. 3,193,548 shares of the company’s stock traded hands, compared to its average volume of 508,030. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 12 month low of $0.56 and a 12 month high of $2.38. The company has a market cap of $29.17 million, a PE ratio of -0.36 and a beta of 0.74. The stock has a 50 day moving average of $1.22 and a 200-day moving average of $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MPM Asset Management LLC boosted its stake in Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. MPM Bioimpact LLC raised its stake in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at $409,000. 64.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HOWL shares. JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America dropped their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.